Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD070
- Development stage
- Preclinical
- Lead developer
- China Medical University
- Modality
- Small Molecules
01
Overview
CD070 is a bioactive compound extracted from Chinese herbal medicine that is being investigated for its potential to enhance cancer immunotherapy. It acts by downregulating programmed cell death protein 1 (PD-1) expression on CD3-stimulated T cells, including CD3+, CD4+, and CD8+ T cell populations. Mechanistically, CD070 inhibits glycolysis in T cells in a dose-dependent manner, thereby modulating immune checkpoint regulation through metabolic pathways.
Beyond the preview
Go deeper on CD070.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD070.